Over many years Protein A resins have become the standard for purification of Monoclonal Antibodies (MAb) due to their high specificity and simplicity. However, concerns over increasing raw material costs, potential leachates and limited caustic stability have left many people searching for suitable alternatives.
In a recent survey of companies involved in MAb purification over 50% stated they were actively seeking to replace Protein A in their downstream process.
This talk covers the challenges faced in the development of Protein A alternatives and reviews on-going work at Prometic to introduce new resins to meet this market demand.
Dr Steve Burton,
CEO, ProMetic BioSciences Ltd
Dr Burton was appointed to the position of Chief Executive Officer of ProMetic BioSciences Ltd in February 2006 having served with the company since its formation. Dr Burton has over 23 years of commercial bioprocess and company management experience.
Dr Burton gained his Ph.D. at the University of Cambridge, UK researching novel affinity ligands for use in protein purification. After spending 2 years as a Research Scientist with Delta Biotechnology Ltd (now Novozymes) Dr Burton joined a new start-up company Affinity Chromatography Ltd as Research Manager and, following the establishment of a successful R&D group which developed Mimetic Ligand™ adsorbents and won the Queens Award for Technological Achievement, he was appointed R&D Director.
Following the acquisition in 1999 of Affinity Chromatography Ltd by ProMetic Life Sciences Inc., Dr Burton has held a variety of positions within the company and has established numerous commercial collaborations with medical and biopharmaceutical companies.
- Why is Protein A so successful?
- Why are so many people looking to replace Protein A?
- Where are we with potential replacements for Protein A resins
- Downstream Scientists
- Purification Development
- Protein Purification
- Manufacturing
- Process Scientists
